Levels of Activated FXII in Survivors of Myocardial Infarction – Association with Circulating Risk Factors and Extent of Coronary Artery Disease

Hans P. Kohler; Angela M. Carter; Max H. Stickland; Peter J. Grant

doi:10.1055/s-0037-1614210

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(01): 14-18
DOI: 10.1055/s-0037-1614210

Review Article

Schattauer GmbH

Levels of Activated FXII in Survivors of Myocardial Infarction – Association with Circulating Risk Factors and Extent of Coronary Artery Disease

Hans P. Kohler

¹From the Unit of Molecular Vascular Medicine, Leeds General Infirmary, Leeds, UK

,

Angela M. Carter

¹From the Unit of Molecular Vascular Medicine, Leeds General Infirmary, Leeds, UK

,

Max H. Stickland

¹From the Unit of Molecular Vascular Medicine, Leeds General Infirmary, Leeds, UK

,

Peter J. Grant

¹From the Unit of Molecular Vascular Medicine, Leeds General Infirmary, Leeds, UK

› Institutsangaben

Abstract

Summary

Little data is available regarding the activated form of factor XIIa (FXIIa) in survivors of myocardial infarction. 292 Caucasian patients characterised for extent of coronary atheroma by angiography and for a past history of myocardial infarction and 77 healthy controls were included in the study. To investigate the relationship between coronary artery disease, activated factor XII and other circulating factors, we studied levels of FXIIa, cholesterol, triglycerides, fasting insulin, fibrinogen, FVII:C, t-PA antigen and PAI-1 antigen. Factor XIIa levels were higher in all patients [2.5 (2.3-2.6) ng/ml] and in patients with a history of MI [2.6 (2.4-2.9) ng/ml] than in controls [1.9 (1.7-2.1) ng/ml], p <0.0001. In patients, FXIIa levels positively correlated with FVII:C, BMI, cholesterol, insulin, PAI-1 antigen, t-PA antigen and triglycerides. In controls FXIIa levels only correlated with PAI-1 antigen and triglycerides. FXIIa levels were strongly associated with extent of coronary stenosis: 2.8 (2.6-3.1) ng/ml and 2.6 (2.3-2.9 ng/ml) in those with 2 and 3 vessels stenosed compared to 2.1 (1.9-2.3) ng/ml in those with 0 vessel stenosed (p = 0.0004). Activated FXII relates to both extent of coronary atheroma and to a past history of myocardial infarction and clusters with features of insulin resistance.

Volltext

Referenzen

References
1 Revak SD, Cochrane CG, Johnston AR, Hugli TE. Structural changes accompanying enzymatic activation of human Hageman factor.. J Clin Invest 1974; 54: 619-27.
2 Revak SD, Cochrane CG. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.. J Clin Invest 1976; 57: 825-60.
3 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasma deficient in factor XI, prekallikrein, or high-molecular weight kininogen.. J Clin Invest 1977; 59: 1167-75.
4 Clarke BJ, Cote HCF, Cool DE. Mapping of a putative surface-binding site of human coagulation factor XII.. J Biol Chem 1989; 264: 11497-502.
5 Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.. J Experimental Medicine 1978; 147: 719-29.
6 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis.. Semin Thromb Hemost 1987; 13: 50-68.
7 Hauert J, Nicoloso G, Schleuning WD, Bachmann F, Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis.. Blood 1989; 73: 994-9.
8 Gordon EM, Hellerstein HK, Ratnoff OD, Arafah BM, Yamashita TS. Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII and spontaneous shortening of prothrombin time in survivors of myocardial infarction.. J Lab Clin Med 1987; 109: 409-13.
9 Pitt B, Mason J, Conti CR, Colman RW. Observations on the plasma kallikrein system during myocardial ischemia.. Trans Assoc Am Phys 1969; 82: 98-107.
10 Kelleher CC, Mitropoulos KA, Imeson J, Meade TW, Martin JC, Reeves BEA, Hughes LO. Hageman factor and risk of myocardial infarction in middle-aged men.. Atherosclerosis 1992; 97: 67-73.
11 Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.. Circulation 1995; 91: 2520-7.
12 Tanaka M, Suzuki A. Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers.. Thromb Res 1994; 76: 289-98.
13 Coppola R, Cristilli P, Cugno M, Ariens RAS, Mari D, Mannucci PM. Measurement of activated factor XII in health and disease.. Blood Coagulation & Fibrinolysis 1996; 7: 530-5.
14 Gershlich A, Syndercombe CD, Mills P, Balcon R. Young infarct patients with single-vessel occlusion do not have an underlying prothrombotic state to explain their coronary occlusion.. Int J Cardiol 1992; 36: 49-56.
15 Ford RP, Esnouf MP, Burgess AI, Sarphie A. An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma.. J Immunoassay 1996; 17: 119-31.
16 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens.. Acta Haematol 1957; 17: 731-6.
17 Mitropoulus KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men.. Atherosclerosis 1989; 76: 203-8.
18 Mitropoulos KA, Martin JC, Burgess AI, Esnouf MP, Stirling Y, Howarth DJ, Reeves BEA. The increased rate of activation of factor XII in late pregnancy can contribute to the increased reactivity of factor VII.. Thromb Haemost 1990; 63: 349-55.
19 Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency.. Atherosclerosis 1992; 95: 119-25.
20 Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary fat intake and plasma factor VII coagulant activity – a predictor of cardiovascular mortality.. Atherosclerosis 1986; 60: 269-71.
21 Radcliffe R, Bagdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by Hageman factor fragments.. Blood 1977; 50: 611-7.
22 Miller GJ, Martin JC, Mitropoulos KA, Esnouf P, Cooper A, Morrissey JH, Howarth DJ, Tuddenham EGD. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.. Blood 1996; 87: 4187-96.
23 Heinrich J, Balleisen J, Schulte H, Assmann H, Vandeloo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.. Arterioscler Thromb 1994; 14: 54-9.
24 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.. Diabetologia 1991; 34: 457-62.
25 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thomson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.. Circulation 1996; 94: 2057-63.
26 Heywood DM, Mansfield MW, Grant PJ. Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus.. Thromb Haemost 1996; 75: 401-6.
27 Juhan-Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atland C. Relationship between plasma insulin, triglycerides, body mass index and plasminogen activator inhibitor 1.. Diabete Met 1987; 9: 263-8.
28 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentration.. J Am Coll Cardiol 1987; 9: 263-8.
29 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction.. N Engl J Med 1985; 313: 1557-63.
30 Johnson O, Mellbring G, Nilsson T. Defective fibrinolysis in survivors of myocardial infarction.. Int J Cardiol 1984; 6: 380-2.
31 Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product and the risk of future myocardial infarction among apparently healthy men.. Circulation 1994; 90: 2236-40.
32 Thomson SG, Kienast J, Pyke SDM, Haverkate F, Vandeloo JWC. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris.. N Engl J Med 1995; 332: 635-41.
33 Jespersen J, Pedersen OD, Gram J, Thomsen KK, Sidelmann J, Kluft C. Deviations in factor XII-dependent plasminogen activator activity in relation to ischemic heart disease and age.. Fibrinolysis 1992; 6: 27-30.
34 Jespersen J, Munkvad S, Pedersen OD, Gram J. Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases.. Ann N Y Acad Sci 1992; 667: 454-6.